Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

120 enrolled

Thoracic

NSCLC

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07251582 2025-11-26

LungTime-C02

Phase 3 Recruiting

156 enrolled

Thoracic

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

112 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1 Withdrawn

Thoracic

Lung Neoplasms

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06614231 2024-09-26

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Phase 3 Not yet recruiting

90 enrolled

Thoracic

Resectable Non-small Cell Lung Cancer

NCT06313541 2024-06-05

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

Phase 2 Recruiting

146 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06424899 2024-05-22

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Phase 2 Recruiting

92 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

89 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06000358 2023-08-21

LUCACRIMUNO

Phase NA Recruiting

120 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT03663166 2023-02-15

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

19 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03823625 2020-03-25

SQUINT

Phase 2 Unknown

112 enrolled

Thoracic

Squamous-Cell Lung Cancer

NCT00391586 2015-08-17

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

Phase 2 Terminated

45 enrolled 4 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

ATLAS

BRIDGE

LungTime-C02

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

LUCACRIMUNO

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Gut Microbiota Reconstruction for NSCLC Immunotherapy

SQUINT

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung